You couldn't make this up. The very group that ordered the report you are referring to, The Association for Accessible Medicines (AAM), is also appealing the in

You couldn't make this up. The very group that ordered the report you are referring to, The Association for Accessible Medicines (AAM), is also appealing the introduction of a law in California that makes pay-for-delay deals with drug companies illegal. Do you understand why I'm calling it naive now? They clearly don't have the public interests in mind at all, just raking in profits, even if it's through mob-like protection fees with incumbents. "The Association for Accessible Medicines (AAM), which represents generic drugmakers, is appealing a December 31 decision by a federal judge that allows California’s new law barring pay-for-delay arrangements between brand-name and generic pharma firms to go forward." "AAM had argued that the law violated the federal government’s right to regulate interstate commerce and the scope of US patents" https://www.centerforbiosimilars.com/news/lobbying-group-appeals-decision-allowing-california-payfordelay-law-to-take-effect https://www.centerforbiosimilars.com/news/lobbying-group-app...